The clinical value of treatment with 153Sm-EDTMP-89SrCl2 joint half volume method for bone metastatic carcinoma

Objective: To explore therapeutic effects and side effects of half quantity 153Sm-EDTMP joint half quantity 89SrCl2 for patients with bone metastatic carcinoma. Methods: 264 patients with extensive bone metastasis were randomly divided into 4 groups. Group Ⅰ: 156 patients were treated with 153Sm-EDTMP, Group Ⅱ: 78 patient were given 89SrCl2, Group Ⅲ: 20 patients accepted the joint half volume therapy, Group Ⅳ (control group): 10 patients were given 4 ml physiological saline. After therapy, all patients were reviewed routine blood test every week in the next 2 months and bone scintigraphy after 36 months. The efficacy of alleviate pain, the time to onset and the duration, myelosuppression were recorded. one-way ANOVA and χ2-test were performed by SAS V8.2. Results: The alleviate pain efficiency of group Ⅰ, Ⅱ, Ⅲ respectively were 79.5% (124/156), 69.2% (54/78), 85% (17/20). No statistical significance among the 3 groups (P>0.05); Significant differences was existed between each group and the control group (P<0.05). The time to onset of group Ⅰ, Ⅱ, Ⅲ were 7.1±3.8 d, 20.5±6.7 d, 8.3±4.5 d. No statistical significance between group Ⅰ and Ⅲ (P>0.05); Group Ⅱ respectively had significant differences with group Ⅰ and Ⅲ (P<0.05). The pain alleviated duration of group Ⅰ, Ⅱ, Ⅲ were 23.6±7.4 d, 70.5±15.6 d, 60.4±12.3 d. No difference between group Ⅱ and Ⅲ (P> 0.05); statistical significance existed between group Ⅰ and group Ⅱ, Ⅲ (P<0.05). The myelosuppression incidence of group Ⅰ, Ⅱ, Ⅲ were 62.8% (98/156), 43.6% (34/78), 40% (8/20). Group Ⅰ respectively compared with group Ⅱ and Ⅲ, there were significant differences between them (P<0.05); No statistical significance between group Ⅱ and Ⅲ (P> 0.05). Conclusion: Half dose 153Sm-EDTMP joint half dose 89SrCl2 therapy can achieve higher efficacy for bone metastatic carcinoma, and fewer side effect of myelosuppression. (authors)